By Michael Avraam , Global Product Manager
A surge in oncology and immune-suppressant therapies and increasing demand for high potency active pharmaceutical ingredients (HPAPIs) is pushing manufacturers to explore innovative containment strategies to meet handling requirements.
As these containment strategies evolve, so too does the role of containment verification. There is a clear need to understand the potential variations in testing and differing interpretations of results.
This article will discuss the key considerations linked to containment performance testing, data collection methods and the interpretation of results.